Patheon Inc

Patheon — Q4 2005 Earnings Presentation

19 slides from Patheon's earnings presentation, Dec 14, 2005

  1. Slide 1: Q4 2005 Financial Results Conference Call

    Q4 2005 FINANCIAL RESULTS CONFERENCE CALL December 14, 2005 11:30 a.m. (EST) Forward-looking Information This presentation contains forward-looking statements with respect to the Company, including its business operations and strategy and financial performance and condition. Although management beli

  2. Slide 2: Presenting on Behalf of Patheon / Agenda

    Presenting on Behalf of Patheon Robert Tedford – Chief Executive Officer Rodger Roden – Chief Financial Officer Nick DiPietro – President and Chief Operating Officer Clive Bennett – President and Chief Operating Officer, MOVA Dr. Shabbir Anik – President, PDS and Chief Scientific Officer Agenda

  3. Slide 3: Opening Comments

    Opening Comments Strategic accomplishments in 2005  Creation of ceph lyo capability in Swindon  Completion of lyo expansion program in Italy Large-volume parenteral start-up in Ferentino  Product carve-outs (2) Opening Comments Operating highlights in 2005  Excellent year in base business 17%

  4. Slide 4: Financial Highlights: Q4 and Fiscal 2005

    Opening Comments Disappointments in 2005 MOVA results Significantly lower-than-anticipated volumes in connection with a new product launch at Whitby FINANCIAL HIGHLIGHTS Q4 and Fiscal 2005 Q4 2005 Webcast Presentation 4

  5. Slide 5: Q4 2005 Highlights and Revenue Growth

    Q4 2005 Highlights  Revenues up 48% to $182M  Internal growth of 15% ($18M)  Strategic growth from MOVA of $41M  EBITDA almost doubled to $26M  EBITDA margin of 14.4% vs. 12.8% before one-time items  Net earnings increased 17% to $5M*; EPS of 5.8* cents vs. 8.9* cents a year ago  Reported net

  6. Slide 6: EBITDA and EBITDA Margin

    EBITDA and EBITDA Margin FY 2005 (%) 13.6% 14.0% 14.1% 14.5% 14.4% 12.9% 12.2% 12.8% * 13.2% 11.2% * * 11.3% 10.2% 10.3% FY FY FY FY FY Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 '01 '02 '03 '04 '05 '04 '04 '04 '04 '05 '05 '05 '05  EBITDA up 104% to $98M  EBITDA margin improvement to 14.0% in 2005 (11.2%* in 2004) r

  7. Slide 7: Reported Net Earnings and EPS

    Reported Net Earnings and EPS FY 2005  Reported net earnings of $22M vs. $11M a year ago  Reported net earnings in 2005 after the following non-recurring items: i) $3M gain on the sale of land reported in Q4 ii) $1M write off of deferred finance costs reported in Q1  Reported EPS of 24.9 cents vs

  8. Slide 8: Depreciation and Amortization; Interest and Tax Rate

    Depreciation and Amortization FY 2005 Depreciation expense of $33M, an increase of $10M or 47% $7M attributable to incremental depreciation of MOVA assets $1.6M attributable to translation to US$ of Canadian and EU depreciation Balance related to capital programs at sites in Italy, Toronto, Cinc

  9. Slide 9: New Financing Arrangements / Operations Overview

    New Financing Arrangements Post Q4, commitments from banking syndicate for $290M in new credit facilities: 5-year term for $50M 6-year term for $165M Revolver of $75M Will replace MOVA debt and one-year bridge facility One-time write-off of deferred financing costs and pre- payment penalties o

  10. Slide 10: Revenue Growth

    Revenue Growth Q4 2005  North American revenues grew $50M or 65% Internal growth of $9M or 12% driven by new product launches and strong PDS growth MOVA contribution of $41M, up from $39M in Q3 volumes lower than expected due to voluntary suspension of Omnicef® powder production in connection w

  11. Slide 11: North America and Europe

    North America FY 2005 North American revenues grew 67% ($197.9M) Incl. MOVA, Rx revenues up 121%, PDS up 37%, OTC up 7% NA internal growth: Rx revenues up 20%, PDS up 26%, OTC up 7% growth in Rx volumes from newly launched products excellent PDS growth on a higher base, reflecting progress at C

  12. Slide 12: Update on MOVA / Capital Investment in Europe

    Capital Investment in Europe FY 2006  Swindon, U.K. new facility dedicated to lyophilized cephalosporins investment of approx. €22M in 2006, substantial financing provided by client complements existing sterile cephalosporin capabilities at Swindon and oral cephalosporin capabilities at Carolina

  13. Slide 13: Update on FDA Warning Letter

    Update on FDA Warning Letter Warning Letter received September 16, 2005 15 days to respond Voluntary suspension of manufacturing to resolve issues Response letter with many commitments submitted on time Response accepted by FDA one week later Update on FDA Warning Letter Full production resume

  14. Slide 14: Review of FY 2005 and Areas of Focus in 2006

    Review of FY 2005 MOVA 2005 financial results impacted by: Client-supplied API shortage issue for Omnicef® resolved at the end of Q3 2005 FDA Warning Letter now resolved; impact on Q4 of 2 cents Trade inventory adjustments for newly launched product, which reduced client demand in second half V

  15. Slide 15: Update on PDS: PDS Revenue Growth

    Update on PDS PDS Revenue Growth FY 2005 Global PDS revenues up 38% YOY to $91.1M North American revenues grew 37% to $73.1M Solid performance in Canada Excellent growth in Cincinnati European revenues grew 46% to $17.9M Momentum at Swindon Progress at start-up operation in Ferentino Q4 2005

  16. Slide 16: PDS Strategic Update

    PDS Strategic Update  Five Centres of Excellence on two continents Canada (Toronto/Whitby/York Mills); Cincinnati, MOVA, Swindon, Ferentino  Strong PDS leadership at each Centre of Excellence Directors at Swindon, Ferentino and MOVA added in 2005  500+ development scientists and technical staff

  17. Slide 17: Four Product Launches in 2005; The Year Ahead in PDS

    Four Product Launches in 2005 2001 to 2005 Approved PDS Commercialization 15* launches since 2001 Including 8 launches in 2004/2005 *14 as at October 31, 2005; one subsequent to year end The Year Ahead in PDS Demand for PDS services expected to remain strong favourable biotech financing environmen

  18. Slide 18: Outlook

    OUTLOOK Outlook Consolidated 2006 results Expect 2006 results to stabilize; growth and profitability expected to improve in 2007 Expect modest improvement in 2006 operating results: Second half stronger than first half Net earnings and EPS similar to 2005 levels excluding one-time gain and antic

  19. Slide 19: Outlook: Q1 2006 Results and 2006 Transition Year

    Outlook Q1 2006 Results Will reflect negative impact of: Normal seasonality and production shutdowns Lower Omnicef® production levels (3¢ EPS) Write-off of deferred financing costs and prepayment penalties ($7.6M) Full quarter of MOVA-related charges (amortization, depreciation and interest) vs

Patheon — Q4 2005 Earnings Presentation on 6ix